Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy
May 18, 2022 (Globe Newswire)
EQNX::TICKER_START (NASDAQ:AVCO), EQNX::TICKER_END Goal of Partnership is to expand Avalon's R&D pipeline to include innovative companion diagnostics in association with the company's ongoing and future cellular immunotherapy clinical programs
Appoints Dr. Hongxing Liu, a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board to further strengthen Avalon's companion diagnostics development capabilities
Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has signed a memorandum of understanding (MOU) with Lu Daopei Hematology Institute ("LDHI") to co-develop precision companion diagnostics (CDx) for chimeric antigen receptor (CAR)-T cell therapies.
LDHI is a premiere hematology research institute with a state-of-the-art facility and expert capabilities for developing precision diagnostics based on personalized genomic, proteomic, transcriptomic and metabolomic platforms. Through this strategic partnership with LDHI, Avalon plans to expand its R&D pipeline to include innovative companion diagnostics in association with its ongoing and future cellular immunotherapy-related clinical programs.
To further strengthen its CDx development capabilities, Avalon has appointed Dr. Hongxing Liu, M.D., M.S., Executive President of LDHI and a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board.
A CDx is a medical device or test, which provides personalized patient information that is essential for the safe and effective use of a highly tailored or targeted therapeutic treatment. A CDx may help a health care professional understand whether the benefits of a therapeutic treatment for a patient would outweigh any potential serious side effects or risks.
CAR T-cell therapies, a number of which have been approved by the U.S. Food and Drug Administration (FDA), are personalized therapies, made from a patient's own cells. CAR-T cell therapy involves bio-engineering and expression of a molecular weapon attacking specific targets on cancer cells. A CDx could help predict whether a patient would respond to a CAR-T cell therapy.
"It is an honor to form this strategic collaboration with the researchers and clinicians at the prestigious Lu Daopei Hematology Institute to advance the clinical development of potentially breakthrough cellular immunotherapies along with companion diagnostics," said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "LDHI will be an ideal partner that has the expertise and capabilities to conduct laboratory and analytic work on cancer biomarkers and precision medicine, as well as access to the clinical and bio-informatics database of the Lu Daopei Hospital. We are especially pleased to welcome Dr. Hongxing Liu to our Scientific and Clinical Advisory Board. Dr. Liu will become an invaluable part and will support our efforts in the development of innovative companion diagnostics in connection with our ongoing and future clinical programs involving cellular immunotherapies."
"Companion diagnostics play an important role in developing effective therapies, by identifying those patients most likely to benefit from biomarker-driven treatments," said Dr. Hongxing Liu, M.D., M.S., Executive President of LDHI. "There is a need for better, faster ways to assess patients' immune profiles to provide personalized immunotherapies. The companion diagnostics we are developing are designed to provide important information about the safe and effective use of a corresponding drug or biological product. Patients with cancer whose care incorporates the use of appropriate companion diagnostics as part of their initial assessment have historically seen a greater survival benefit than those who were not tested. I look forward to working with Avalon to develop these innovative companion diagnostics for CAR-T cell therapies, as well as advancing the bioinformatics database and testing kits."
The agreement between Avalon GloboCare and LDHI is subject to negotiation and execution of definitive documentation acceptable to both parties.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX(TM)), and regenerative therapeutics. For more information about Avalon GloboCare, please visit http://www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com
$AVCO is trading way below its intrinsic value.
Avalon GloboCare Corp. (NASDAQ: $AVCO ) is making progress and gaining recognition in the biotechnology and healthcare industries. The stock exhibits massive growth potential, and as of May 6, post its patent filings, the stock has gained 11.24% in just 5 days, making it one of the best penny stocks to buy in May. https://finance.yahoo.com/news/10-penny-stocks-buy-may-151001107.html
$AVCO in News Article: "10 Penny Stocks to Buy in May" @yahoo
Avalon GloboCare Corp. (NASDAQ:AVCO) provides biotechnology development and healthcare services in the United States.
https://finance.yahoo.com/news/10-penny-stocks-buy-may-151001107.html
$AVCO the Company has jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, https://finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html
$AVCO NICE GREEN START UP +8.87%
$AVCO Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications
https://finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html
$AVCO Co-inventors are leading international universities and cellular therapy developers; Patent applications cover three types of cellular therapies and related technologies https://finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html
HUGE $AVCO #Patent NEWS! Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications https://finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
$AVCO huge news out this morning: Co-inventors are leading international universities and cellular therapy developers
Patent applications cover three types of cellular therapies and related technologies
FREEHOLD, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. Patents were filed with the U.S. Patent and Trademark Office (USPTO), the China National Intellectual Property Administration (CNIPA), and under the Patent Cooperation Treaty (PCT) covering 36 countries.
The new intellectual property covers three core patent families:
Engineering and bio-manufacturing of novel chimeric antigen receptor (CAR) T-cells related to the mRNA-based Flash-CARTM cellular therapy platform. This technology has been applied to Avalon’s AVA-011 CAR-T cell therapy candidate, which is currently at the process development stage to generate cGMP-grade CAR-T cells for upcoming first-in-human clinical trials.
Soluble, antibody-like cytokine/chemokine decoy receptors derived using the QTY protein design, with potential applications including mitigation of the “cytokine storm” associated with COVID-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies.
Novel S-layer coated emulsome technology (SLET)-derived fusion proteins intended for mucosal vaccine development, which is designed to trigger robust protective immune responses at the predominant sites of pathogen infection. The SLET platform provides a “molecular GPS system” to guide the trafficking and delivery of a payload to a targeted destination in the body.
“These latest patent applications solidify and expand our robust IP portfolio, both in the U.S. and internationally,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We are especially honored to partner with several leading global academic researchers and institutions in the field of cell therapy, as co-inventors of the technologies. We believe these patent applications will extend our geographic IP protection and are timed to maximize the duration of the patents for decades to come. These patents are within our core competencies in the areas of CAR-T, QTY protein design and S-layer technologies, thereby enhancing our position as a leader in immuno-oncology and cellular medicines. Collectively, we believe each of these patents covers therapies and technologies that target large, addressable markets. They are all supported by strong preclinical data as we rapidly advance towards first-in-human clinical trials.”
$AVCO GOING TO HIT $1++ VERY SOON! LOAD AND BEHOLD!
$AVCO thin to 1.00's here!
$AVCO ABOUT TO WAKE UP SOON IN A BIG WAY.
$AVCO hidden diamond in a rough load and hold
$AVCO Big things are imminent here folks!
$AVCO trading has stabilized... Looks better, let's see if the chart can continue its turn upwards.
Light trading today, but a nice BID at 0.80... $AVCO
Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies.
Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.
The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T candidate.
AVA-011 is currently at the IND-enabling process development stage.
The platform uses next-generation CAR technology to modify patients' T or universal-donor NK cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, allowing for more rapid and lower-cost bio-manufacturing the cell therapy products.
$AVCO Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors. https://finance.yahoo.com/news/avalon-globocare-adds-car-nk-165721173.html
CORPORATE OVERVIEW
Avalon GloboCare Corp. is a clinical-stage, leading CellTech bio-developer dedicated to
*Advancing and Empowering Innovative, Transformative Immune Effector Cell Therapy
*Exosome Technology
Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth, development, as well as competitiveness in healthcare and CellTech industry markets.
http://www.avalon-globocare.com/aboutus.html
Be sure to take a look at the AVCO company website for a comprehensive review of their bio technologies suite and objectives.
Link: http://www.avalon-globocare.com/
From the site:
Avalon achieves and fosters seamless integration of unique verticals to bridge and accelerate innovative research, bio-process development, clinical programs and product commercialization.
Avalon’s upstream innovative research includes:
Co-development of Avalon Clinical-grade Tissue-specific Exosome (ACTEXTM) with Weill Cornell Medicine
Novel therapeutic and diagnostic targets development utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT)
Co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK and other immune effector cell therapeutic modalities with Arbele Corp.
Avalon’s midstream bio-processing and bio-production facility is located in Nanjing, China with state-of-the-art, automated GMP and QC/QA infrastructure for standardized bio-manufacturing of clinical-grade cellular products involved in our clinical programs in immune effector cell therapy, regenerative therapeutics, as well as bio-banking.
Avalon’s downstream medical team and facility consists of top-rated affiliated hospital network and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics.
$AVCO CEO believes in the future...
Avalon’s Chairman converts $3.0 million of debt into common stock at $1.25 per share showing continued confidence and support of the business
The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T candidate.
AVA-011 is currently at the IND-enabling process development stage.
The platform uses next-generation CAR technology to modify patients' T or universal-donor NK cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, allowing for more rapid and lower-cost bio-manufacturing the cell therapy products.
$AVCO holding steady... and a great outlook for 2022.
As we head into 2022, we believe we have a number of important upcoming milestones that have the potential to continue to drive significant value for our shareholder
Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe
Intended SenlangBio acquisition terminated, eliminating potential 80 million share issuance
$AVCO Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.
Avalon GloboCare Corp (NASDAQ: $AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies. https://finance.yahoo.com/news/avalon-globocare-adds-car-nk-165721173.html
Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.
The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T candidate.
AVA-011 is currently at the IND-enabling process development stage.
Related: Avalon GloboCare Adds Cell Therapy-Based Candidates For Cancer With SenlangBio Acquisition: Highlights. $AVCO
$AVCO Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform https://finance.yahoo.com/news/avalon-globocare-adds-car-nk-165721173.html
$AVCO trading just over 75% of its 10-day average volume with less than 2 hours left in the day. Nice chart uptrend.
Clinical development of CAR-NK cell therapy planned in collaboration with the Company’s clinical partner, Lu Daopei Hospital, as a potential treatment for hematologic malignancies and other unmet medical areas
AVCO
Very significant news report from AVCO today for the company's ongoing advancements for cancer treatments via its highly promising immuno-cell therapy techniques. Also great to see another highly qualified member added to the company's scientific team.
Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies
Leveraging Avalon’s existing Flash-CARTM technology platform to develop next-generation mRNA-based CAR-NK cellular therapeutics
Clinical development of CAR-NK cell therapy planned in collaboration with the Company’s clinical partner, Lu Daopei Hospital, as a potential treatment for hematologic malignancies and other unmet medical areas
Appoints Dongfang Liu, Ph.D., a world-class scientist and expert in CAR-NK technology, to Avalon’s Scientific and Clinical Advisory Board
FREEHOLD, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies.
Natural killer (NK) cells constitute an important component of the immune system. NK cells seek out abnormal cells, including cancerous cells, and destroy them. However, cancer cells are often capable of “masking” themselves to evade attack by NK cells. By adding a “Chimeric Antigen Receptor” (CAR) to a patient’s own or universal-donor NK cells, these engineered CAR-NK cells are designed to “unmask,” recognize and destroy a patient’s specific tumor surface targets.
Avalon is leveraging its mRNA-based FLASH-CAR™ platform to develop autologous and universal (“off-the-shelf”) CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors. Avalon plans to expand its clinical program in collaboration with its major clinical trial partner, the Lu Daopei Hospital.
The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon’s lead CAR-T candidate, part of the Company’s proprietary mRNA-based FLASH-CAR™ platform. AVA-011 is currently at the IND-enabling, process development stage, which is expected to produce clinical-grade CAR-T cells for an upcoming clinical trial in patients with hematological malignancies. The platform uses next generation CAR technology to modify patients’ T or universal-donor NK cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, allowing for more rapid and lower-cost bio-manufacturing of the cell therapy products.
To further strengthen its CAR-NK development capabilities, Avalon has appointed Dr. Dongfang Liu to its Scientific and Clinical Advisory Board. Dr. Liu is currently an Associate Professor and Director of Immunoassay Development Program at the Department of Pathology, Immunology and Laboratory Medicine at The Rutgers University New Jersey Medical School. Dr. Liu’s research expertise is focused on the immunobiology of NK and CAR-NK, with more than 20 years of experience in NK cell research. Dr. Liu is a prolific author in top-tier journals including Nature Immunology, Immunity, Nature Medicine, Nature Communications, JACI, and PNAS. Dr. Liu also serves on the editorial boards of several scientific journals and as a reviewer for scientific journals and grant agencies.
“CAR-NK represents a powerful and innovative tool in the fight against cancer, and we believe our mRNA-based FLASH-CAR™ platform will enable us to develop best-in-class therapies,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We are especially pleased to welcome Dr. Dongfang Liu to our Scientific and Clinical Advisory Board. Dr. Liu will become an invaluable part of the team in expanding and supporting Avalon’s pipeline. We also appreciate the support of our world-class clinical partners, including the researchers and clinicians at the prestigious Lu Daopei Hospital, as we develop our cellular immuno-oncology programs for hematologic malignancies as well as other unmet medical needs,” added Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit http://www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com
https://www.globenewswire.com/newsroom/ti?nf=ODQ3NDQ4MyM0NzI1NTg4IzIxODQyMDc=
https://ml.globenewswire.com/media/ZDZiODk3MGMtNmM3Zi00NDU3LWFlODYtZWNmMjNlNTc5ZTY1LTExOTU3NjE=/tiny/Avalon-GloboCare-Corp-.png
Source: Avalon GloboCare Corp.
$AVCO #breakingNews : Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies
https://finance.yahoo.com/news/avalon-globocare-expands-cellular-immuno-140000211.html
$AVCO NEWS: Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies
https://finance.yahoo.com/news/avalon-globocare-expands-cellular-immuno-140000211.html
$AVCO big news here: Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies https://finance.yahoo.com/news/avalon-globocare-expands-cellular-immuno-140000211.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
$AVCO trading 2.3x its 10-day average volume with less than 2.5 hours left in the day, UP almost 7% and thin on the ASK to the high of the day.
$AVCO trading over 2x its 10-day average volume with less than an hour left in the day...nice volume!
$AVCO trading just over its 10-day average volume with less than 3 hours left in the day... UP over 8% with a tight spread on the BID and ASK.
Yes, now over 60%...in 1.5 hours. $AVCO
$AVCO Nice volume in the first 30 minutes
$AVCO provided a year-end business update. https://finance.yahoo.com/news/avalon-globocare-provides-end-business-140000433.html
Strong start here!
AVCO
$AVCO trading over 50% of its 10-day average volume within the first 40 minutes.
$AVCO trading 75% of its 10-day average volume with less than 3 hours left in the day, UP almost 3%. Nice BID at 0.72 and thin on the ASK.
Looking for $AVCO updates in the near future...
“Given our rapid progress this past year, our goal for 2022 is to focus on our core programs to drive innovation and bring about advanced technologies and new medicines to patients."
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
632
|
Created
|
03/07/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |